Market capitalization | DKK198.44b |
Enterprise Value | DKK205.44b |
P/E (TTM) P/E ratio | 39.13 |
EV/FCF (TTM) EV/FCF | 89.51 |
EV/Sales (TTM) EV/Sales | 11.48 |
P/S ratio (TTM) P/S ratio | 11.09 |
P/B ratio (TTM) P/B ratio | 8.47 |
Dividend yield | 1.40% |
Last dividend (FY22) | DKK6.00 |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
19 Analysts have issued a Novonesis forecast:
19 Analysts have issued a Novonesis forecast:
Dec '23 |
+/-
%
|
||
Revenue | 17,899 17,899 |
-
|
|
Gross Profit | 9,786 9,786 |
-
|
|
EBITDA | 5,834 5,834 |
-
|
EBIT (Operating Income) EBIT | 4,445 4,445 |
-
|
Net Profit | 3,024 3,024 |
-
|
In millions DKK.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Novonesis A/S engages in the era of biosolutions. It innovate and develop transformative biosolutions that improve the way the world produces, consumes, and lives. The company was founded on January 29, 2024 is headquartered in Lyngby, Denmark.
Head office | Denmark |
CEO | Ester Baiget |
Employees | 6,756 |
Website | www.novonesis.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.